GSK plc
GLAXF
$26.08
-$0.80-2.98%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.12B | 42.05B | 40.96B | 40.23B | 40.10B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.12B | 42.05B | 40.96B | 40.23B | 40.10B |
| Cost of Revenue | 11.82B | 11.59B | 11.60B | 11.31B | 11.31B |
| Gross Profit | 31.30B | 30.47B | 29.36B | 28.93B | 28.79B |
| SG&A Expenses | 11.89B | 11.71B | 13.69B | 13.86B | 13.90B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.81B | -1.08B | -638.86M | -491.90M | -660.75M |
| Total Operating Expenses | 30.69B | 30.51B | 32.70B | 32.46B | 32.32B |
| Operating Income | 12.43B | 11.54B | 8.26B | 7.77B | 7.79B |
| Income Before Tax | 9.75B | 9.21B | 5.98B | 5.35B | 4.41B |
| Income Tax Expenses | 1.46B | 1.25B | 823.22M | 742.23M | 666.49M |
| Earnings from Continuing Operations | 8.29K | 7.96K | 5.16K | 4.60K | 3.74K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -755.24M | -745.63M | -729.05M | -623.14M | -481.12M |
| Net Income | 7.53B | 7.22B | 4.43B | 3.98B | 3.26B |
| EBIT | 12.43B | 11.54B | 8.26B | 7.77B | 7.79B |
| EBITDA | 17.42B | 16.21B | 13.16B | 11.94B | 11.61B |
| EPS Basic | 1.86 | 1.78 | 1.09 | 0.97 | 0.80 |
| Normalized Basic EPS | 1.62 | 1.49 | 0.99 | 0.94 | 0.97 |
| EPS Diluted | 1.83 | 1.75 | 1.07 | 0.96 | 0.79 |
| Normalized Diluted EPS | 1.60 | 1.47 | 0.97 | 0.92 | 0.96 |
| Average Basic Shares Outstanding | 16.20B | 16.27B | 16.31B | 16.33B | 16.31B |
| Average Diluted Shares Outstanding | 16.44B | 16.49B | 16.53B | 16.55B | 16.52B |
| Dividend Per Share | 0.87 | 0.84 | 0.82 | 0.79 | 0.78 |
| Payout Ratio | 44.90% | 45.82% | 72.89% | 79.74% | 95.77% |